- Home
- JYD vs COCP Comparison
JYD vs COCP Comparison
Compare JYD & COCP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- JYD
- COCP
- Stock Information
- Founded
- JYD 2001
- COCP 2006
- Country
- JYD China
- COCP United States
- Employees
- JYD N/A
- COCP N/A
- Industry
- JYD Oil Refining/Marketing
- COCP Biotechnology: Pharmaceutical Preparations
- Sector
- JYD Consumer Discretionary
- COCP Health Care
- Exchange
- JYD Nasdaq
- COCP Nasdaq
- Market Cap
- JYD 17.8M
- COCP 15.4M
- IPO Year
- JYD 2023
- COCP N/A
- Fundamental
- Price
- JYD $0.19
- COCP $1.73
- Analyst Decision
- JYD
- COCP Strong Buy
- Analyst Count
- JYD 0
- COCP 1
- Target Price
- JYD N/A
- COCP $6.00
- AVG Volume (30 Days)
- JYD 1.6M
- COCP 28.5K
- Earning Date
- JYD 08-12-2025
- COCP 08-13-2025
- Dividend Yield
- JYD N/A
- COCP N/A
- EPS Growth
- JYD N/A
- COCP N/A
- EPS
- JYD N/A
- COCP N/A
- Revenue
- JYD $77,444,271.00
- COCP N/A
- Revenue This Year
- JYD N/A
- COCP N/A
- Revenue Next Year
- JYD N/A
- COCP N/A
- P/E Ratio
- JYD N/A
- COCP N/A
- Revenue Growth
- JYD 13.54
- COCP N/A
- 52 Week Low
- JYD $0.09
- COCP $1.12
- 52 Week High
- JYD $8.00
- COCP $3.26
- Technical
- Relative Strength Index (RSI)
- JYD 39.83
- COCP 58.30
- Support Level
- JYD $0.22
- COCP $1.59
- Resistance Level
- JYD $0.25
- COCP $1.76
- Average True Range (ATR)
- JYD 0.02
- COCP 0.12
- MACD
- JYD 0.01
- COCP 0.01
- Stochastic Oscillator
- JYD 19.61
- COCP 38.89
About JYD Jayud Global Logistics Limited
Jayud Global Logistics Ltd is an end-to-end supply chain solution provider in China, with a focus on providing cross-border logistics services. The company offers freight forwarding services, supply chain management, and other value-added services.
About COCP Cocrystal Pharma Inc.
Cocrystal Pharma Inc is a biotechnology company discovering and developing novel antiviral therapeutics that target the replication machinery of influenza viruses, hepatitis C viruses, and noroviruses. It employs structure-based technologies and Nobel Prize-winning expertise to create first and in-class antiviral drugs. It is developing CC-31244, an investigational, oral, broad-spectrum replication inhibitor called a non-nucleoside inhibitor (NNI).